Psoriasis and Inflammatory Bowel Disease (IBD): Understanding the Gut-Skin Connection
Psoriasis and inflammatory bowel disease (IBD) – the umbrella term for Crohn’s disease and ulcerative colitis – turn up together far more often than chance alone would explain, and the overlap runs deeper than two unrelated conditions simply coinciding in the same person. Both are driven by an immune system that has turned against the body’s own tissue, just in different organs: the skin in psoriasis, the digestive tract in IBD. Large population studies now confirm that having psoriasis measurably raises the odds of developing IBD, and the relationship appears to run in both directions. This guide walks through what the evidence actually shows, the warning signs worth watching for, which psoriasis treatments need extra caution if IBD is also in the picture, and how this connection fits into an integrative, Ayurvedic treatment plan.
Why Psoriasis and IBD Are Linked
Psoriasis belongs to a broader family of autoimmune diseases in which the immune system mistakes healthy tissue for a threat and keeps attacking it. Crohn’s disease and ulcerative colitis work on the same basic principle, except the target is the lining of the intestines rather than the skin. It is a well-documented pattern in immunology that having one immune-mediated inflammatory condition raises the odds of developing a second, often in a completely different organ system, and psoriasis and IBD are one of the better-studied examples of exactly this pattern.
How Common Is IBD in People With Psoriasis?
Crohn’s Disease and Ulcerative Colitis Risk
A systematic review and meta-analysis published in JAMA Dermatology pooled multiple case-control and cohort studies and found a consistent, significant association in both directions. Pooling case-control studies, the odds of Crohn’s disease were 70% higher in people with psoriasis (OR 1.70) and ulcerative colitis 75% higher (OR 1.75). Pooling cohort studies, which track new diagnoses forward in time, the risk of developing Crohn’s disease was more than double (RR 2.53) and ulcerative colitis 71% higher (RR 1.71) than in people without psoriasis. One Asian case-control study was an outlier, finding slightly lower odds of Crohn’s disease in psoriasis, a reminder that most evidence here comes from Western and Middle Eastern populations and may not translate perfectly everywhere.
Psoriatic Arthritis and Disease Severity Raise the Risk Further
A 2024 retrospective cohort study of over 61,000 adults with psoriasis, published in Therapeutic Advances in Chronic Disease, found IBD in 2.4% of people with psoriasis compared with 1.6% of matched people without it (OR 1.47). The link was considerably stronger in two groups: people with psoriatic arthritis had more than double the odds of IBD (OR 2.27) compared with psoriasis patients without joint involvement, and people with severe psoriasis (defined by the need for systemic therapy or phototherapy) had dramatically higher odds of IBD than those with mild, skin-only disease. The authors also noted that the association was more pronounced for Crohn’s disease than for ulcerative colitis, which matches the pattern seen in the broader meta-analysis above.
Shared Biology: The IL-23/Th17 and TNF Connection
Researchers point to overlapping immune biology rather than pure coincidence. Psoriasis and IBD both involve excessive activity along the IL-23/Th17 inflammatory pathway and elevated tumor necrosis factor-alpha (TNF-α), the same signaling molecules modern psoriasis biologics are designed to block. Shared genetic susceptibility plays a role too: variants near genes such as IL23R, JAK2, STAT3, and TNFAIP3 have each been linked independently to both conditions. This is also why the gut is a genuine research focus in psoriasis more broadly; our article on psoriasis and gut health covers the gut-skin axis in more general terms, short of a formal IBD diagnosis.
Warning Signs Worth Watching For
IBD symptoms are easy to dismiss as a stomach bug, stress, or diet, which is exactly why they are often missed for months or years. If you have psoriasis, it is worth raising any of the following with a doctor rather than waiting for them to resolve on their own:
- Persistent diarrhea lasting more than a few weeks, or diarrhea that recurs in cycles
- Abdominal pain or cramping, often in the lower abdomen, that doesn’t settle with usual remedies
- Blood or mucus in the stool, even in small or intermittent amounts
- Unexplained weight loss or persistent fatigue not accounted for by anything else
- Urgency or a frequent, pressing need to use the bathroom
- Low-grade fever that comes and goes alongside digestive symptoms
None of these symptoms confirm IBD on their own, but any combination appearing together, and lasting beyond a couple of weeks, is a reasonable trigger to ask for a referral to a gastroenterologist, particularly if you also have psoriatic arthritis or more severe skin disease.
Treatment Considerations: Choosing Therapy Safely When Both Conditions Are Present
This is the single most practical implication of the psoriasis-IBD link, and it is worth knowing before you start or switch a systemic psoriasis medication. IL-17 inhibitors, a biologic class that includes secukinumab and ixekizumab, carry a labeled warning for new-onset or worsening inflammatory bowel disease; case reports and pharmacovigilance data describe IBD flares, and occasionally new IBD diagnoses, emerging after starting this drug class. For this reason, IL-17 inhibitors are generally used with caution, or avoided altogether, in people who already have IBD or a strong personal or family history of it.
By contrast, several drug classes used for moderate-to-severe psoriasis are also approved treatments for Crohn’s disease or ulcerative colitis in their own right, making them a logical first choice when both conditions coexist: TNF inhibitors (such as adalimumab and infliximab), ustekinumab (which blocks IL-12/IL-23), and some IL-23 inhibitors such as risankizumab and guselkumab. Methotrexate is sometimes used for psoriasis as well, though it is less IBD-specific than the biologics above. The right choice depends on disease severity, prior treatment response, and a gastroenterologist’s input, and should always be decided with your treating doctor. Our comparison of Ayurveda vs biologics for psoriasis goes into more detail on how these systemic options are generally weighed.
Topical treatments, phototherapy, and Ayurvedic management of the skin do not carry this particular risk, since they act locally or do not work through the same systemic immune pathways implicated in IBD.
Diagnosis, Monitoring, and Cost in India
If IBD is suspected, the usual first step is a gastroenterologist consultation, who will typically order a fecal calprotectin test, a stool-based marker of intestinal inflammation widely available at diagnostic labs across Bangalore and other Indian cities, generally costing ₹1,500 to ₹3,000. A raised result, or strong clinical suspicion alone, usually leads to a colonoscopy with biopsy for a definitive diagnosis, commonly costing ₹6,000 to ₹15,000 depending on the facility and whether sedation is included. These are meaningful expenses but modest next to the cost of a missed or delayed diagnosis. Ongoing monitoring, once diagnosed, is coordinated by the gastroenterologist, typically alongside periodic blood work your dermatologist can also use while managing your psoriasis.
How This Fits an Integrative, Ayurvedic Approach
In our clinical assessment, psoriasis is most closely correlated with Kushta, reflecting a deeper Vata-Kapha-Pitta imbalance addressed through the longer-term protocols described in our Ayurvedic psoriasis treatment in Bangalore guide. Gut health has always held a central place in this framework: classical Ayurvedic physiology treats Agni, the digestive fire, and the buildup of Ama, or improperly digested metabolic waste, as closely tied to skin health, which is one reason a gut-focused intake has long been routine for psoriasis patients here, independent of modern IBD research. In practice, that means digestion, bowel habits, and bloating get asked about as routinely as the plaques themselves, since those clues can point toward an issue worth confirming with a gastroenterologist. What integrative care does not mean is delaying or substituting conventional IBD treatment: when Crohn’s disease or ulcerative colitis is confirmed, gastroenterology-led treatment continues alongside Ayurvedic management of the skin, not instead of it.
When to See a Doctor
Ask for a gastroenterology referral if you have psoriasis and notice persistent diarrhea, recurring abdominal pain, blood in the stool, unexplained weight loss, or any combination of these lasting more than two to three weeks. This is especially worth prioritizing if you also have psoriatic arthritis, more severe skin disease, or a family history of Crohn’s disease or ulcerative colitis. A straightforward stool test and, if needed, a colonoscopy usually settle the question. You can also book a consultation for a personalized assessment that looks at your psoriasis alongside your broader digestive and immune health.
Frequently Asked Questions
1. Does psoriasis cause IBD, or does IBD cause psoriasis?
Neither directly causes the other. Research shows a strong association, meaning the two occur together far more often than chance would predict, most likely because they share overlapping immune pathways (the IL-23/Th17 axis and TNF-alpha) and some common genetic susceptibility, not because one triggers the other.
2. How common is IBD in people with psoriasis?
A 2024 cohort study of over 61,000 psoriasis patients found IBD in about 2.4% of them versus 1.6% of matched controls, and meta-analyses found 70 to 150% higher odds of Crohn’s disease and ulcerative colitis in people with psoriasis.
3. Which psoriasis biologic should I avoid if I have IBD?
IL-17 inhibitors such as secukinumab and ixekizumab carry a labeled warning for new or worsening IBD and are generally used with caution, or avoided, in people with a personal or strong family history of it. TNF inhibitors, ustekinumab, and some IL-23 inhibitors are approved for both psoriasis and IBD and are often preferred instead, but the final choice should be made with your treating doctor.
4. Does psoriatic arthritis increase the risk of IBD further?
Yes. Studies found that people with psoriatic arthritis have roughly double the odds of developing IBD compared with people whose psoriasis affects only the skin, likely reflecting more widespread, systemic inflammation.
5. Will treating my IBD improve my psoriasis, or vice versa?
Sometimes, but not reliably. Because the conditions share inflammatory pathways, some treatments (certain TNF inhibitors or ustekinumab) can help both at once. Still, each condition needs its own active monitoring rather than assuming progress in one will resolve the other.
6. Should everyone with psoriasis be screened for IBD?
Routine screening isn’t recommended for everyone with psoriasis, since most never develop IBD. Prompt evaluation is reasonable for anyone with psoriasis who develops persistent digestive symptoms, with closer awareness for those with psoriatic arthritis, severe skin disease, or a family history of IBD.
Sources and References
- “Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis,” JAMA Dermatology, 2019.
- Shani, U. et al., “The association between psoriasis, psoriasis severity, and inflammatory bowel disease: a population-based analysis,” Therapeutic Advances in Chronic Disease, 2024.
- “An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients,” PMC, 2023.
- “Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection,” PMC, 2024.
- “Psoriasis,” NHS; “Psoriasis,” DermNet NZ; American Academy of Dermatology, psoriasis comorbidities resources.
This article is intended for general educational purposes and does not replace personalized medical advice. Anyone with symptoms of IBD or psoriasis should consult a qualified doctor for proper testing and diagnosis.
